Melanoma is widely thought to be immunogenic, supported by clinical observations such as the frequency of spontaneous tumor regressions, the prevalence of melanoma in immunosuppressed patients, and the partial success of clinically-available immune modulatory therapies such as the polyclonal immune activating cytokines IFNa-2b and IL-2 [4, 5, 6, 7] . Host adaptive immune responses have been described in melanoma with a main focus on melanoma specific T cell responses [8, 9] , and supported by successful case scenarios using immunotherapeutic strategies such as dendritic cell vaccines, adoptive T cell therapies, and CTLA4 monoclonal antibodies [7, 10, 11, 12, 13] .